Evaxion announces several key executive management changes to optimize value from its proprietary AI-Immunology platform and pipeline. Christian Kanstrup has stepped down as Chief Executive Officer, CEO, and Evaxion has initiated the search for a new permanent CEO to lead its next phase of growth and to accelerate value creation from its AI-based technologies and assets developed over the past 17 years. Dr. Birgitte Rono, Evaxion’s Chief Scientific Officer, has been appointed interim CEO. Dr. Rono has been with Evaxion since 2017 and joined its Executive Management in 2021. She brings deep scientific and strategic expertise to the role.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Expands R&D with New Group A Streptococcus Vaccine Program
- Evaxion Biotech expands R&D pipeline with new vaccine program
- Evaxion Secures Gates Foundation Grant for Innovative Polio Vaccine
- Evaxion Biotech receives grant funding to design new polio vaccine
- Evaxion Biotech’s Earnings Call Highlights Progress and Challenges